A carregar...
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient
Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC). As the clinical use of sorafenib increases, many adverse effects have been reported, such as hand-foot skin reaction, diarrhea, anorexia, asthenia, alope...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Baishideng Publishing Group Co., Limited
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3020384/ https://ncbi.nlm.nih.gov/pubmed/21246003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v17.i2.267 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|